Tumor necrosis factor α (TNF-α)-targeted therapies have expanded the therapeutic options for patients with inflammatory bowel disease (IBD), rheumatoid arthritis (RA), psoriasis, and psoriatic arthritis (PsA) and have significantly improved patients’ quality of life. Paradoxically, anti-TNF-α agents may induce psoriatic eruptions or worsen preexisting psoriatic skin disease. Currently, there is no standard approach for the management of TNF inhibitor-induced psoriasis. Here, we conduct a literature review on TNF inhibitor-induced psoriasis and introduce a novel treatment algorithm for maintaining otherwise effective anti-TNF therapy versus switching to a different class as appropriate in the management of patients with IBD, RA, psoriasis, or PsA.
CampaMRyanCMenterA. An overview of developing TNF-alpha targeted therapy for the treatment of psoriasis. Expert Opin Investig Drugs. 2015;24(10):1343–1354.
2.
FeldmanMTaylorPPaleologEBrennanFMMainiRN. Anti-TNF alpha therapy is useful in rheumatoid arthritis and Crohn’s disease: analysis of the mechanism of action predicts utility in other diseases. Transplant Proc. 1998;30(8):4126–4127.
3.
FeldmanSRGordonKBBalaM. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial. Br J Dermatol. 2005;152(5):954–960.
4.
StrandVSharpVKoenigAS. Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment. Ann Rheum Dis. 2012;71(7):1143–1150.
5.
HoldamASBagerPDahlerupJF. Biological therapy increases the health-related quality of life in patients with inflammatory bowel disease in a clinical setting. Scand J Gastroenterol. 2016;51(6):706–711.
6.
KoJMGottliebABKerbleskiJF. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J Dermatolog Treat. 2009;20(2):100–108.
7.
BrownGWangELeonA. Tumor necrosis factor-alpha inhibitor-induced psoriasis: systematic review of clinical features, histopathological findings, and management experience. J Am Acad Dermatol. 2017;76(2):334–341.
8.
CollamerANGuerreroKTHenningJSBattafaranoDF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum. 2008;59(7):996–1001.
9.
CollamerANBattafaranoDF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheum. 2010;40(3):233–240.
10.
ShmidtEWetterDAFergusonSBPittelkowMR. Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-alpha inhibitors: the Mayo Clinic experience, 1998 to 2010. J Am Acad Dermatol. 2012;67(5):e179–e185.
11.
JoyauCVeyracGDixneufVJollietP. Anti-tumour necrosis factor alpha therapy and increased risk of de novo psoriasis: is it really a paradoxical side effect?Clinical and experimental rheumatology. 2012;30(5):700–706.
12.
LagaACVleugelsRAQureshiAAVelazquezEF. Histopathologic spectrum of psoriasiform skin reactions associated with tumor necrosis factor-alpha inhibitor therapy. A study of 16 biopsies. Am J Dermatopathol. 2010;32(6):568–573.
13.
SeneschalJMilpiedBVergierBLepreuxSSchaeverbekeTTaiebA. Cytokine imbalance with increased production of interferon-alpha in psoriasiform eruptions associated with antitumour necrosis factor-alpha treatments. Br J Dermatol. 2009;161(5):1081–1088.
FlendrieMVissersWHCreemersMCde JongEMvan de KerkhofPCvan RielPL. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther. 2005;7(3):R666–R676.
16.
SfikakisPPIliopoulosAElezoglouAKittasCStratigosA. Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum. 2005;52(8):2513–2518.
17.
HarrisonMJDixonWGWatsonKD. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2009;68(2):209–215.
18.
HernandezMVSanmartiRCaneteJD. Cutaneous adverse events during treatment of chronic inflammatory rheumatic conditions with tumor necrosis factor antagonists: study using the Spanish registry of adverse events of biological therapies in rheumatic diseases. Arthritis Care Res. 2013;65(12):2024–2031.
19.
KoizumiHTokurikiAOyamaN. Certolizumab pegol, a pegylated anti-TNF-alpha antagonist, caused de novo-onset palmoplantar pustulosis followed by generalized pustular psoriasis in a patient with rheumatoid arthritis. J Dermatol. 2017;44(6):723–724.
AfzaliAWheatCLHuJKOlerudJELeeSD. The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: a single academic center case series. J Crohns Colitis. 2014;8(6):480–488.
22.
GuerraIAlgabaAPerez-CalleJL. Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 21 cases. J Crohns Colitis. 2012;6(5):518–523.
23.
GuerraIPérez-JeldresTIborraM. Incidence, clinical characteristics, and management of psoriasis induced by Anti-TNF therapy in patients with inflammatory bowel disease: a nationwide cohort study. Inflamm Bowel Dis. 2016;22(4):894–901.
24.
EickstaedtJBKillpackLTungJDavisDHandJLTollefsonMM. Psoriasis and Psoriasiform eruptions in pediatric patients with inflammatory bowel disease treated with anti-tumor necrosis factor alpha agents. Pediatr Dermatol. 2017;34(3):253–260.
25.
GottliebABEvansRLiS. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2004;51(4):534–542.
26.
NapolitanoMBalatoNCasoF. Paradoxical onset of psoriatic arthritis during treatment with biologic agents for plaque psoriasis: a combined dermatology and rheumatology clinical study. Clin Exp Rheumatol. 2017;35(1):137–140.
ConradCBoymanOTonelG. Alpha1beta1 integrin is crucial for accumulation of epidermal T cells and the development of psoriasis. Nat Med. 2007;13(7):836–842.
29.
ConradCDi DomizioJMylonasA. TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis. Nat Commun. 2018;9(1):25.
30.
LadoyanniENambiR. Psoriasis exacerbated by interferon-alpha in a patient with chronic myeloid leukemia. J Drugs Dermatol. 2005;4(2):221–222.
31.
MaHLNapierataLStedmanN. Tumor necrosis factor alpha blockade exacerbates murine psoriasis-like disease by enhancing Th17 function and decreasing expansion of Treg cells. Arthritis Rheum. 2010;62(2):430–440.
32.
TillackCEhmannLMFriedrichM. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-gamma-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment. Gut. 2014;63(4):567–577.
33.
ChanJRBlumenscheinWMurphyE. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med. 2006;203(12):2577–2587.
34.
LeeETrepicchioWLOestreicherJL. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med. 2004;199(1):125–130.
35.
TabarkiewiczJPogodaKKarczmarczykAPozarowskiPGiannopoulosK. The role of IL-17 and Th17 lymphocytes in autoimmune diseases. Arch Immunol Ther Exp. 2015;63(6):435–449.
36.
DuffinKCKruegerGG. Genetic variations in cytokines and cytokine receptors associated with psoriasis found by genome-wide association. J Invest Dermatol. 2009;129(4):827–833.
37.
SherlockMEWaltersTTabbersMM. Infliximab-induced psoriasis and psoriasiform skin lesions in pediatric Crohn disease and a potential association with IL-23 receptor polymorphisms. J Pediatr Gastroenterol Nutr. 2013;56(5):512–518.
38.
FryLBakerBS. Triggering psoriasis: the role of infections and medications. Clin Dermatol. 2007;25(6):606–615.
39.
BongartzTSuttonAJSweetingMJBuchanIMattesonELMontoriV. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295(19):2275–2285.
40.
DommaschEDAbuabaraKShinDBNguyenJTroxelABGelfandJM. The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol. 2011;64(6):1035–1050.
41.
CarterJD. Tumour necrosis factor inhibition causing psoriasis? A more plausible explanation exists. Ann Rheum Dis. 2006;65(12):1680–1680.
42.
InmanRDChiuB. Early cytokine profiles in the joint define pathogen clearance and severity of arthritis in Chlamydia-induced arthritis in rats. Arthritis Rheum. 2006;54(2):499–507.
43.
NajarianDJGottliebAB. Connections between psoriasis and Crohn’s disease. J Am Acad Dermatol. 2003;48(6):805–821; quiz 822-804.
44.
KimballABGladmanDGelfandJM. National Psoriasis Foundation clinical consensus on psoriasis co-morbidities and recommendations for screening. J Am Acad Dermatol. 2008;58(6):1031–1042.
45.
MakredesMRobinsonDJr.BalaMKimballAB. The burden of autoimmune disease: a comparison of prevalence ratios in patients with psoriatic arthritis and psoriasis. J Am Acad Dermatol. 2009;61(3):405–410.
46.
LeeFIBellarySVFrancisC. Increased occurrence of psoriasis in patients with Crohn’s disease and their relatives. Am J Gastroenterol. 1990;85(8):962–963.
47.
YatesVMWatkinsonGKelmanA. Further evidence for an association between psoriasis, Crohn’s disease and ulcerative colitis. Br J Dermatol. 1982;106(3):323–330.
48.
VedakPKroshinskyDSt. JohnJXavierRJYajnikVAnanthakrishnanAN. Genetic basis of TNF-α antagonist associated psoriasis in inflammatory bowel diseases: a genotype-phenotype analysis. Aliment Pharmacol Ther. 2016;43(6):697–704.
49.
PariserDMBagelJGelfandJM. National Psoriasis Foundation clinical consensus on disease severity. Arch Dermatol. 2007;143(2):239–242.
50.
MaserEADecondaDLichtigerSUllmanTPresentDHKornbluthA. Cyclosporine and infliximab as rescue therapy for each other in patients with steroid-refractory ulcerative colitis. Clin Gastroenterol Hepatol. 2008;6(10):1112–1116.
51.
LeblancSAllezMSeksikP. Successive treatment with cyclosporine and infliximab in steroid-refractory ulcerative colitis. Am J Gastroenterol. 2011;106(4):771–777.
52.
DenadaiRTeixeiraFVSteinwurzFRomitiRSaad-HossneR. Induction or exacerbation of psoriatic lesions during anti-TNF-alpha therapy for inflammatory bowel disease: a systematic literature review based on 222 cases. J Crohns Colitis. 2013;7(7):517–524.
53.
SheuJSDivitoSJEnamandramMMerolaJF. Dapsone therapy for pustular psoriasis: case series and review of the literature. Dermatology (Basel, Switzerland). 2016;232(1):97–101.
54.
LorenzMWozelGSchmittJ. Hypersensitivity reactions to dapsone: a systematic review. Acta Derm Venereol. 2012;92(2):194–199.
55.
StotlandMShalitaARKisslingRF. Dapsone 5% gel: a review of its efficacy and safety in the treatment of acne vulgaris. Am J Clin Dermatol. 2009;10(4):221–227.
56.
RobinsonAVan VoorheesASHsuS. Treatment of pustular psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2012;67(2):279–288.
57.
DaiY-XChenC-C. Flare-up of pustular psoriasis after ustekinumab therapy: case report and literature review [published online ahead of print June 1, 2018]. Dermatologica Sinica. 2018.
58.
BaganzLRichterAKekowJ. Long-term effectiveness of tocilizumab in patients with rheumatoid arthritis, stratified by number of previous treatment failures with biologic agents: results from the German RABBIT cohort. Rheumatol Int. 2018. 38(4):579–587.
59.
EmeryPKeystoneETonyHP. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis. 2008;67(11):1516–1523.
60.
WakabayashiHHasegawaMNishiokaYMinamiYNishiokaKSudoA. Clinical outcome in patients with rheumatoid arthritis switched to tocilizumab after etanercept or infliximab failure. Clin Rheumatol. 2013;32(2):253–259.
61.
EmeryPGottenbergJERubbert-RothA. Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study. Ann Rheum Dis. 2015;74(6):979–984.
62.
SolimanMMHyrichKLLuntM. Rituximab or a second anti-tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti-tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register. Arthritis Care Res (Hoboken). 2012;64(8):1108–1115.
63.
Gomez-ReinoJJManeiroJRRuizJ. Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: the MIRAR Study. Ann Rheum Dis. 2012;71(11):1861–1864.
64.
GenoveseMCBeckerJCSchiffM. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med. 2005;353(11): 1114–1123.
65.
WeinblattMSchiffMGoldmanA. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Ann Rheum Dis. 2007;66(2):228–234.
66.
van VollenhovenRFFleischmannRCohenS. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012;367(6):508–519.
67.
BurmesterGRBlancoRCharles-SchoemanC. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet. 2013;381(9865):451–460.
68.
SinghJAHossainATanjong GhogomuE. Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2017;3:CD012591.
69.
Sanso SuredaARocamora DuránVSapiña CamaróARoyo EscosaVBosque LópezMJ. Ustekinumab in a patient with Crohn’s disease and anti-TNF-alpha-induced psoriasis [in Spanish]. Gastroenterol Hepatol. 2011;34(8):546–550.
70.
PuigLMorales-MúneraCELópez-FerrerAGeliC. Ustekinumab treatment of TNF antagonist-induced paradoxical psoriasis flare in a patient with psoriatic arthritis: case report and review. Dermatology. 2012;225(1):14–17.
71.
KopylovUAfifWCohenA. Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn’s disease—the McGill experience. J Crohns Colitis. 2014;8(11):1516–1522.
72.
ChuDHVan VoorheesASRosenbachM. Treatment of refractory tumor necrosis factor inhibitor-induced palmoplantar pustulosis: a report of 2 cases. Arch Dermatol. 2011;147(10):1228–1230.
73.
FeaganBGRubinDTDaneseS. Efficacy of vedolizumab induction and maintenance therapy in patients with ulcerative colitis, regardless of prior exposure to tumor necrosis factor antagonists. Clin Gastroenterol Hepatol. 2017;15(2):229–239 e5.
74.
SandsBEFeaganBGRutgeertsP. Effects of vedolizumab induction therapy for patients with Crohn’s disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 2014;147(3):618–627 e3.
75.
SandsBESandbornWJVan AsscheG. Vedolizumab as induction and maintenance therapy for Crohn’s disease in patients naive to or who have failed tumor necrosis factor antagonist therapy. Inflamm Bowel Dis. 2017;23(1):97–106.
76.
FeaganBGRutgeertsPSandsBE. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369(8):699–710.
77.
KavanaughAMcInnesIBMeasePJ. Efficacy of subcutaneous secukinumab in patients with active psoriatic arthritis stratified by prior tumor necrosis factor inhibitor use: results from the randomized placebo-controlled FUTURE 2 study. J Rheumatol. 2016;43(9):1713–1717.
78.
PelechasEMemiTVoulgariPVDrososAA. A case of recalcitrant psoriatic arthritis to TNF inhibitors improved after administration of secukinumab, an IL-17A inhibitor. Rheumatol Ther. 2017;4(2):509–513.
79.
KawalecPHolkoPMoćkoPPilcA. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis. Rheumatol Int. 2018;38(2):189–201.
80.
BlauveltAReichKTsaiTF. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: results from the CLEAR study. J Am Acad Dermatol. 2017;76(1):60–69 e9.
81.
NashPKirkhamBOkadaM. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. Lancet. 2017;389(10086):2317–2327.
82.
GriffithsCEReichKLebwohlM. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386(9993):541–551.
83.
EdwardsCJBlancoFJCrowleyJ. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3). Ann Rheum Dis. 2016;75(6):1065–1073.
84.
ReichKGooderhamMBewleyA. Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study. J Eur Acad Dermatol Venereol. 2018;32(3):397–402.
85.
RitchlinCRahmanPKavanaughA. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis. 2014;73(6):990–999.
86.
BogaardsNAde RieMA. Psoriasiform eruption and worsening of pustulosis palmoplantaris after treatment with two Anti-TNF-alpha inhibitors, followed by successful treatment with ustekinumab. Dermatol Ther (Heidelb). 2016;6(4):683–688.
87.
GerdesSFrankeJDommSMrowietzU. Ustekinumab in the treatment of palmoplantar pustulosis. Br J Dermatol. 2010;163(5):1116–1118.
88.
SuhHYAhnJYParkMYYounJI. Exacerbation of infliximab-induced paradoxical psoriasis after ustekinumab therapy. J Dermatol. 2018;45(3):332–333.
89.
MeasePJGottliebABvan der HeijdeD. Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis. Ann Rheum Dis. 2017;76(9):1550–1558.
90.
MeasePGenoveseMCGladsteinG. Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum. 2011;63(4): 939–948.
91.
GladmanDRigbyWAzevedoVF. Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med. 2017;377(16):1525–1536.
92.
MeasePHallSFitzGeraldO. Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med. 2017;377(16):1537–1550.
93.
BlauveltAPappKAGriffithsCE. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405–417.
94.
ReichKArmstrongAWFoleyP. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76(3):418–431.
95.
MegnaMBalatoARaimondoABalatoN. Guselkumab for the treatment of psoriasis. Expert Opin Biol Ther. 2018;18(4):459–468.
96.
GottenbergJEBrocqOPerdrigerA. Non-TNF-targeted biologic vs a second anti-TNF drug to treat rheumatoid arthritis in patients with insufficient response to a first anti-TNF drug: a randomized clinical trial. JAMA. 2016;316(11):1172–1180.
97.
WeiWKnappKWangL. Treatment persistence and clinical outcomes of tumor necrosis factor inhibitor cycling or switching to a new mechanism of action therapy: real-world observational study of rheumatoid arthritis patients in the united states with prior tumor necrosis factor inhibitor therapy. Adv Ther. 2017;34(8):1936–1952.
98.
RutgeertsPSandbornWJFeaganBG. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462–2476.
99.
KawalecPMockoP. An indirect comparison of ustekinumab and vedolizumab in the therapy of TNF-failure Crohn’s disease patients. J Comp Eff Res. 2018;7(2):101–111.
100.
KimballABPappKAWasfiY. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. J Eur Acad Dermatol Venereol. 2013;27(12):1535–1545.
101.
PuglieseDGuidiLFerraroPM. Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study. Aliment Pharmacol Ther. 2015;42(7):880–888.
102.
FeuersteinJDCheifetzAS. Miscellaneous adverse events with biologic agents (excludes infection and malignancy). Gastroenterol Clin North Am. 2014;43(3):543–563.
103.
IborraMBeltranBBastidaGAguasMNosP. Infliximab and adalimumab-induced psoriasis in Crohn’s disease: a paradoxical side effect. J Crohns Colitis. 2011;5(2):157–161.
104.
AndrisaniGMarzoMCellenoL. Development of psoriasis scalp with alopecia during treatment of Crohn’s disease with infliximab and rapid response to both diseases to ustekinumab. Eur Rev Med Pharmacol Sci. 2013;17(20):2831–2836.
105.
LeeHYWooCHHawS. Paradoxical flare of psoriasis after ustekinumab therapy. Ann Dermatol. 2017;29(6):794–795.
106.
WhitlockSMEnosCWArmstrongAW. Management of psoriasis in patients with inflammatory bowel disease: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2018;78(2):383–394.
107.
ThomasLCanoui-PoitrineFGottenbergJE. Incidence of new-onset and flare of preexisting psoriasis during rituximab therapy for rheumatoid arthritis: data from the French AIR registry. J Rheumatol. 2012;39(5):893–898.
108.
DassSVitalEMEmeryP. Development of psoriasis after B cell depletion with rituximab. Arthritis Rheum. 2007;56(8):2715–2718.
109.
JostCHermannJCaelen LelSGraningerW. New onset psoriasis in a patient receiving abatacept for rheumatoid arthritis. BMJ Case Rep. 2009;2009:pii:bcr09.2008.0845.
110.
UrsiniFNatySRussoEGrembialeRD. Abatacept in psoriatic arthritis: case report and short review. J Pharmacol Pharmacother. 2013;4(suppl 1):S29–S32.
111.
Palmou-FontanaNSanchez GavinoJAMcGonagleDGarcia-MartinezEIniguez de Onzono MartinL. Tocilizumab-induced psoriasiform rash in rheumatoid arthritis. Dermatology (Basel, Switzerland). 2014;228(4):311–313.
112.
LaurentSLe ParcJMClericiTBrebanMMaheE. Onset of psoriasis following treatment with tocilizumab. Br J Dermatol. 2010;163(6):1364–1365.
